Lakefront Biotherapeutics (GLPGF) Revenue (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Revenue for 13 consecutive years, with $14.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue fell 80.95% year-over-year to $14.1 million in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 210.29% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 321.2% from the prior year.
• Revenue was $14.1 million for Q2 2026 at Lakefront Biotherapeutics, up from $7.6 million in the prior quarter.
• Over five years, Revenue peaked at $1.0 billion in Q4 2025 and troughed at -$172.3 million in Q4 2022.
• A 5-year average of $145.0 million and a median of $70.9 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue tumbled 141.4% in 2024 and soared 2516.76% in 2025, its largest moves.
• Over 5 years, Revenue stood at -$172.3 million in 2022, then soared by 439.52% to $585.1 million in 2023, then tumbled by 93.15% to $40.1 million in 2024, then soared by 2516.76% to $1.0 billion in 2025, then plunged by 98.66% to $14.1 million in 2026.
• The last three Revenue figures came in at $14.1 million (Q2 2026), $7.6 million (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.